Bernd J. Krause

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial).

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts

Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts.

A VISION Substudy of Reader Agreement on⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for¹⁷⁷Lu-PSMA-617 Radioligand Therapy

Translational assessment of a DATA-functionalized FAP inhibitor with facile 68Ga-labeling at room temperature

Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline

DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis

DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Imaging of prostate cancer

PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor

Kamingespräch „§ 13 (2b) AMG in der nuklearmedizinischen Therapie” – eine Follow-up-Veranstaltung der NuklearMedizin 2020 – Digital

Der Chemokinrezeptor CXCR4 – seine Entwicklung und Bedeutung in der nuklearmedizinischen Theranostik

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status

⁶⁸Ga‐Labelled Tropane Analogues for the Visualization of the Dopaminergic System

Konsensusempfehlung zur strukturierten Befunderstellung onkologischer PET-Hybridbildgebung

Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up